Screener
Capricor Therapeutics CAPR Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-060382
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Receivables | 59,167 | 10,308,655 |
| Prepaid expenses and other assets | 979,776 | 55,473 |
| Accounts payable and accrued expenses | (3,081,283) | 1,315,268 |
| Net cash used in operating activities | (29,254,891) | (6,433,520) |
| Cash flows from investing activities: | ||
| Purchase of marketable securities | (174,893,062) | (18,181,600) |
| Proceeds from sales and maturities of marketable securities | 30,998,448 | 43,212,559 |
| Purchases of property and equipment | (5,121,709) | (896,007) |
Item 1. Financial Statements.
FAQ
- What is Capricor Therapeutics's operating cash flow?
- Capricor Therapeutics (CAPR) reported operating cash flow of -$29.25M in Q1 2026.
- How has Capricor Therapeutics's operating cash flow changed year-over-year?
- Capricor Therapeutics's operating cash flow decreased by 354.7% year-over-year, from -$6.43M to -$29.25M.
- What is the long-term trend for Capricor Therapeutics's operating cash flow?
- Over 3 years (2021 to 2025), Capricor Therapeutics's operating cash flow has grown at a 60.7% compound annual growth rate (CAGR), from -$16.81M to -$69.81M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Capricor Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude